Table 3.
Ovarian cancer | Gaucher | ||||
CM10 | Q10 | CM10/Q10 | |||
label | Ciphergen A | 43 | 19 | 57 | 57 |
Ciphergen B | 37 | 15 | 47 | 46 | |
Ciphergen C | 41 | 13 | 50 | 30 | |
chip | Ciphergen A | 6 | 57 | 69 | 8 |
Ciphergen B | 10 | 35 | 52 | 7 | |
Ciphergen C | 0 | 15 | 16 | 10 | |
label:chip | Ciphergen A | 0 | 0 | 0 | 3 |
Ciphergen B | 0 | 0 | 0 | 0 | |
Ciphergen C | 0 | 0 | 0 | 0 | |
label | Cromwell A | 153 | 17 | 142 | 43 |
Cromwell B | 112 | 12 | 95 | 40 | |
Cromwell C | 67 | 8 | 61 | 29 | |
chip | Cromwell A | 0 | 0 | 0 | 22 |
Cromwell B | 0 | 0 | 0 | 37 | |
Cromwell C | 0 | 0 | 0 | 26 | |
label:chip | Cromwell A | 0 | 0 | 0 | 1 |
Cromwell B | 0 | 0 | 0 | 0 | |
Cromwell C | 0 | 0 | 0 | 0 |
Number of peaks with an adjusted p-value < 0,2 (ANOVA and correction for multiple testing) for different peak detection settings (A-C for both Ciphergen and Cromwell) for CM10, Q10, and CM10/Q10 (ovarian cancer dataset) and the Gaucher dataset. An ANOVA was performed for label effect (patient versus control), chip (array) effect and interaction effect label:chip.